Sutro Biopharma
STROSutro Biopharma is a clinical-stage oncology company that utilizes its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+, to develop next-generation therapeutics.
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Sutro Biopharma is a clinical-stage oncology company that utilizes its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+, to develop next-generation therapeutics. The company specializes in creating site-specific antibody-drug conjugates (ADCs), bispecific ADCs, and immunostimulatory ADCs with optimized therapeutic profiles. Their core value proposition lies in the ability to rapidly design and manufacture homogeneous molecules that target clinically validated cancer pathways where current treatments are suboptimal.
Sutro maintains a specialized position as a leader in cell-free protein synthesis, offering a unique ability to produce homogeneous ADCs with precise drug-antibody ratios that are difficult to achieve with conventional cell-based methods.
Questions, answered.
- What is Sutro Biopharma's market cap?
- Sutro Biopharma (STRO) has a market capitalization of $496.9M and trades on NASDAQ.
- What is Sutro Biopharma's revenue and profitability?
- Sutro Biopharma generated $99.6M in trailing twelve-month revenue with a net loss of $153.6M, representing a net margin of -154.2%, with free cash flow of -$151.6M. These figures are based on the Q1 2026 filing.
- Who are Sutro Biopharma's competitors?
- Sutro Biopharma's key competitors include Genmab A/S, Pfizer Inc., AstraZeneca PLC, and others. These companies compete in similar markets and product categories.
- Who does Sutro Biopharma partner with?
- Sutro Biopharma's notable partners include Astellas Pharma Inc., Vaxcyte, Inc., Merck & Co., Inc., and others.
- Where is Sutro Biopharma headquartered?
- Sutro Biopharma is headquartered in United States of America and employs approximately 300 people. It has been publicly traded since 2018.
